A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080

1. Signed informed consent before the trial; fully understood the trial content, procedures, and possible adverse reactions; able to complete the study per protocol.
2. Healthy participants aged 18-55 years (inclusive) at the time of signing informed consent.
3. At screening, male body weight ≥ 50.0 kg, female body weight ≥ 45.0 kg, and BMI 19.0-28.0 kg/m² (inclusive).
4. Healthy participants confirmed by the investigator at screening and baseline to have no clinically significant abnormalities, including medical history, general physical examination, vital signs, laboratory tests (blood routine, urinalysis, blood biochemistry, and coagulation function), and ECG.
5. Participants of childbearing potential (including partners) agreed to have no plans for pregnancy or sperm/egg donation from informed consent until 3 months after the last dose, and voluntarily used highly effective contraception (including partners); female participants of childbearing potential must have a negative serum HCG test within 7 days before enrollment and must be non-lactating.

Exclusion Criteria:

1. Any clinically significant or interfering disease involving the cardiovascular, endocrine, nervous, digestive, respiratory, urogenital, hematologic, immunologic, psychiatric, or metabolic systems.
2. Surgery within 6 months before screening, planned surgery during the study, or prior surgery affecting gastrointestinal absorption (e.g., gastrectomy, enterectomy, bariatric surgery).
3. Blood donation or major blood loss (≥ 400 mL), transfusion, or use of blood products within 3 months before screening.
4. Allergic constitution, including severe drug allergy or drug hypersensitivity; history of allergy to HRS-8080, rifampicin, rifamycin, or their excipients.
5. Frequent use of sedatives, hypnotics, or other addictive drugs; history of drug abuse within 1 year before screening; positive urine drug abuse screen.
6. Use of hepatotoxic drugs (e.g., isoniazid, pyrazinamide, methotrexate, leflunomide, valproate, amiodarone, acetaminophen, dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) for > 7 consecutive days within 2 months before screening.
7. Participation in any clinical trial with an investigational drug within 3 months before first dosing.
8. Use of any drug altering hepatic enzyme activity within 28 days before dosing.
9. Use of any prescription drug or herbal medicine within 1 month, or any OTC drug or food supplement (including vitamins, calcium tablets) within 2 weeks before first dosing.
10. Smoking > 5 cigarettes/day within 3 months before screening and unable to stop tobacco use during the study.
11. Frequent alcohol use within 6 months before screening (> 14 units/week; 1 unit = 285 mL beer, 25 mL spirits, or 100 mL wine) and unable to stop alcohol during the study; positive alcohol breath test.
12. Clinically significant abnormalities in vital signs, physical examination, 12-lead ECG, abdominal ultrasound, chest X-ray, blood routine, blood biochemistry, urinalysis, or coagulation at screening.
13. Any positive result for HBsAg, anti-HCV, anti-TP, or anti-HIV.
14. Intake of > 8 servings (1 serving = 250 mL) of caffeine-containing beverages or equivalent within 48h before first dosing and unable to abstain during the study.
15. Intake of methylxanthine-containing beverages or foods (e.g., coffee, tea, cola, chocolate) within 48h before first dosing until study withdrawal and unwilling to stop.
16. Intake of grapefruit-containing beverages or foods within 7 days before first dosing until study withdrawal and unwilling to stop.
17. Special dietary requirements or inability to comply with a standardized diet.
18. Live/attenuated vaccine within 3 months before first dosing, or planned live/attenuated/inactivated vaccine during the study (until last follow-up).
19. Dysphagia.
20. History of needle or blood phobia, poor venous access, difficult blood collection, or intolerance to venipuncture.
21. Female participants who are pregnant or lactating.
22. Any other condition deemed unsuitable for study participation by the investigator.